IL24 and renal carcinoma: Sorafenib tosylate (a potent multi kinase inhibitor and a clinically proven FDA approved drug in hepatocellular carcinoma) treatment in combination with MDA-7/IL-24 has also been reported to kill renal carcinoma cells in vivo in animal models resulting in prolonged survival [150].